Publications in collaboration with researchers from Université Catholique de Louvain (27)

2024

  1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future Oncology, Vol. 20, Núm. 13, pp. 799-809

  2. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

  3. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  4. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 10, pp. 2910-2921

  5. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 187, pp. 128-138

  6. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

  7. Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators

    Journal of Prevention of Alzheimer's Disease

  8. Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey)

    Clinical Endocrinology, Vol. 101, Núm. 2, pp. 180-190

2022

  1. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease

    Gut, Vol. 71, Núm. 9, pp. 1856-1866

2021

  1. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798

  2. Expert consensus guidelines on minimally invasive donor hepatectomy for living donor liver transplantation from innovation to implementation: A joint initiative from the international laparoscopic liver society (ILLS) and the Asian-Pacific hepato-pancreato-biliary association (A-PHPBA)

    Annals of Surgery, Vol. 273, Núm. 1, pp. 96-108

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

    Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310

  5. Is chelation therapy a potential treatment for parkinson’s disease?

    International Journal of Molecular Sciences, Vol. 22, Núm. 7

  6. Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance

    Journal of Clinical Oncology, Vol. 39, Núm. 25, pp. 2779-2790

2020

  1. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 395, Núm. 10218, pp. 132-141

  2. Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial

    Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197

2019

  1. Deficient IL-6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis

    Hepatology Communications, Vol. 3, Núm. 7, pp. 867-882

2018

  1. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

    New England Journal of Medicine, Vol. 378, Núm. 6, pp. 518-528

  2. PEG-PGA enveloped octaarginine-peptide nanocomplexes: An oral peptide delivery strategy

    Journal of Controlled Release, Vol. 276, pp. 125-139